AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20463186
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation (2 x 500 mg to 2 x 1000 mg)
Trial: 20463186
Drug: RTX 2
RxNorm normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTX 2 x 1000 mg
Trial: 16855773
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng (KRG) 1,000 mg (3 times daily)
Trial: 16163531
Drug: Bupropion (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (150 mg SR)
Trial: 16163531
Drug: Methamphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (0, 15, and 30 mg)
Trial: 10091831
Drug: i.c. adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.c. adenosine (2.4 mg/min for 10 min starting 20 min before the first occlusion)
Trial: 7594412
Drug: Thiazide diuretics
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretics or beta-blockers (first- or second-line drugs)
Trial: 7594412
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of diastolic hypertension
Trial: 7594412
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of isolated systolic hypertension
Trial: 28577292
Drug: Teneligliptin 20
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20 mg/day for 12 weeks
Trial: 20204975
Drug: Full intervention
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full intervention (peer-modelling materials, daily pedometer goals, rewards)
Trial: 20204975
Drug: No-rewards intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-rewards intervention (peer-modelling materials, daily pedometer goals, no rewards)
Trial: 20204975
Drug: No-rewards intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-rewards intervention (after taper phase)
Trial: 20204975
Drug: Full intervention
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full intervention (after taper phase)
Trial: 19751560
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment without low-dose hydrocortisone)
Trial: 17299470
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of oral riboflavin and other B-group vitamins daily for 14 days
Trial: 2839538
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg iv bolus dose of methoxamine
Trial: 30457655
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab dosing
Trial: 30457655
Drug: Treat-and-extend (T&E)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treat-and-extend (T&E) ranibizumab dosing
Trial: 25764996
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 1 year in infants (m/f: 11/8)
Trial: 25764996
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 2 years in prepubertal children (m/f: 14/14)
Trial: 24092509
Drug: Propofol/remifentanil intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/remifentanil intravenous anaesthesia
Trial: 21045734
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with amlodipine/valsartan 10/320 mg (after dose increase at week 2) and hydrochlorothiazide 12.5 mg (added at week 4)
Trial: 21045734
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg (added at week 4)
Trial: 21045734
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with amlodipine/valsartan 10/320 mg and hydrochlorothiazide 12.5 mg
Trial: 21045734
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg
Trial: 8695601
Drug: Polysaccharide-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide-free diet with breakfast supplement (biscuits made from wheat, potato, or banana flours; moist-heat-processed wheat or maize flours)
Trial: 23128847
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AT and EMS (AT+EMS)
Trial: 22320418
Drug: Latanoprost 0.005%/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC)
Trial: 22320418
Drug: Dorzolamide hydrochloride
RxNorm normalized name: Dorzolamide Hydrochloride
DrugBank: Dorzolamide (DB00869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC)
Trial: 21145518
Drug: Stretching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching treatment performed by physical therapists
Trial: 21145518
Drug: Stretching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching treatment performed by parents
Trial: 15640320
Drug: CRQ-Self-Administered (CRQ-SA)
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRQ-Self-Administered (CRQ-SA)
Trial: 15640320
Drug: CRQ-Interviewer Administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRQ-Interviewer Administered (CRQ-IA)
Trial: 8792352
Drug: Opsite 3000TM
RxNorm normalized name: DRESSING,OPSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opsite 3000TM (transparent moisture vapor permeable dressings, MVPD) changed weekly
Trial: 24506274
Drug: Anesthetic gel
RxNorm normalized name: Topicaine 4% Topical Anesthetic Gel
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic gel (5% lidocaine and 5% prilocaine) applied in the sulcus 5 minutes before the procedure
Trial: 24506274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anesthetic gel)
Trial: 20694407
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of PUFAs
Trial: 18405951
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 mcg (for patients aged < 11 years) or 400 mcg once daily
Trial: 12053591
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (two puffs four times daily, 0.002 g/puff)
Trial: 8519669
Drug: Primary treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary treatment: debulking surgery followed by platinum-based chemotherapy
Trial: 27663942
Drug: Treatment responders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment responders from the acute trial
Trial: 20664284
Drug: Telmisartan-based therapy
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan-based therapy
Trial: 20664284
Drug: CCB-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB-based therapy
Trial: 15180174
Drug: Sigmasporin Microoral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sigmasporin Microoral 100 mg
Trial: 15180174
Drug: Sandimmune Neoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune Neoral 100 mg
Trial: 11475748
Drug: Oxymatrine 600
RxNorm normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine 600 mg per day intramuscularly
Trial: 11475748
Drug: General liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General liver protective agents (vitamins)
Trial: 28093896
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) and topical administration of tranexamic acid (TXA) (15 mg/kg i.v. and 1.0 g topically)
Trial: 24635496
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (400 μg) 4 hourly
Trial: 24635496
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of intracervical Foley catheter and intravaginal misoprostol (400 μg) 4 hourly
Trial: 19486375
Drug: PALS after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALS after treatment modelling intervention
Trial: 8924192
Drug: Nortriptyline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline with medication clinic (no IPT)
Trial: 8924192
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with medication clinic
Trial: 22835900
Drug: Biocompatible PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible PD fluids (neutral-pH, low glucose degradation product 1.5% glucose solution; 1.1% amino acid solution; 7.5% icodextrin)
Trial: 20644121
Drug: AIDA-2000 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AIDA-2000 treatment including anthracycline-based consolidation and all-trans retinoic acid (ATRA) for 15 days during each consolidation.
Trial: 20644121
Drug: AIDA-2000 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AIDA-2000 treatment for high-risk patients including anthracycline-based consolidation and ATRA.
Trial: 20644121
Drug: AIDA-0493 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AIDA-0493 treatment including cytarabine-containing regimens for high-risk patients.
Trial: 20644121
Drug: AIDA-0493 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AIDA-0493 treatment including cytarabine-containing regimens for low/intermediate-risk patients.
Trial: 9607056
Drug: Five-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-valent pneumococcal conjugate vaccine (PCV); three doses separated by two months; types 6B, 14, 18C, 19F, and 23F
Trial: 9607056
Drug: Saline placebo;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo; three doses
Trial: 2096747
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose atracurium/lidocaine combination
Trial: 31426362
Drug: ω3‐PUFA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω3‐PUFA alone (800 mg DHA and 225 mg EPA daily)
Trial: 30246185
Drug: Fo3 (fixed-on-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fo3 (fixed-on-3) implants
Trial: 30246185
Drug: Fo4 (fixed-on-4)
RxNorm normalized name: 2-Phenylbenzopyran-4-one
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fo4 (fixed-on-4) implants
Trial: 23895820
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (VitD3) supplementation, 2,000 IU oral daily for 6 weeks
Trial: 14684758
Drug: Asian ginseng
RxNorm normalized name: ASIAN GINSENG
DrugBank: Panax ginseng whole (DB14284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asian ginseng (0, 1, 2, and 3 g)
Trial: 10871810
Drug: Neuromotor rehabilitative
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromotor rehabilitative treatment
Trial: 9180065
Drug: Flexibility exercises
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexibility exercises and relaxation therapy for 12 weeks
Trial: 9180065
Drug: Graded aerobic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded aerobic exercise after crossover from flexibility treatment
Trial: 9180065
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise treatment
Trial: 8466022
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g/250 mL normal saline)
Trial: 8466022
Drug: Saline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (250 mL normal saline)
Trial: 28340145
Drug: NKTR-181 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 (100 mg, 200 mg, 400 mg)
Trial: 28340145
Drug: NKTR-181 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 (400 mg)
Trial: 26135957
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of SCREAM Theater intervention
Trial: 26135957
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of SCREAM Theater intervention
Trial: 22773673
Drug: Mini-screw implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-screw implant
Trial: 16515105
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine, 1 ml (30 mg) of ketorolac and 9 ml of saline intra-articularly (Group C)
Trial: 16515105
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of intra-articular saline and 10 ml of 0.25% bupivacaine (Group B)
Trial: 16515105
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of intra-articular saline (Group A)
Trial: 14527527
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with sertraline and cognitive-behavior therapy (CBT)
Trial: 10515020
Drug: Radiofrequency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency treatment (n = 15)
Trial: 3046626
Drug: metoprolol (M)
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol (M) 200 mg SR qd
Trial: 3046626
Drug: low-Na/high-K salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-Na/high-K salt (S) 2 g bid
Trial: 30654882
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Trial: 28882385
Drug: Vibrating mesh
RxNorm normalized name: MIcroAir Vibrating Mesh Nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrating mesh (VM) with 5000 μg salbutamol
Trial: 28882385
Drug: Jet nebulizers
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet nebulizers (JN) with 5000 μg salbutamol
Trial: 28882385
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler with AeroChamber Vent (MDI-AV) with 1600 μg salbutamol
Trial: 24273930
Drug: Urtica dioica
RxNorm normalized name: Urtica Dioica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urtica dioica leaf extract (500 mg capsule every 8 hours for 3 months)
Trial: 20467757
Drug: Palonosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.25 mg i.v. bolus 30 min before TMZ)
Trial: 12239424
Drug: Seresis (antioxidative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seresis (antioxidative combination containing carotenoids, vitamins C and E, selenium, and proanthocyanidins)
Trial: 7923235
Drug: Vigabatrin (gamma-vinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (gamma-vinyl GABA) treatment, initial dose of 10 mg/kg per day progressively increased up to a maximum of 140 mg/kg per day, in addition to conventional concomitant therapy.
Trial: 12410546
Drug: valepotriates (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valepotriates (mean daily dose: 81.3 mg)
Trial: 12410546
Drug: diazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam (mean daily dose: 6.5 mg)
Trial: 25106708
Drug: PLIF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLIF with porous ceramic corundum implants
Trial: 11856620
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated influenza vaccine (LIV)
Trial: 11856620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LIV and IIV (LIV/IIV)
Trial: 2190537
Drug: Cepharanthin (CEP)
RxNorm normalized name: Cephalanthus occidentalis bark extract
DrugBank: Cepharanthine (DB16824)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cepharanthin (CEP) 60 mg/day p.o.
Trial: 2190537
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no CEP administration)
Trial: 340643
Drug: Intramuscular nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nalbuphine (3 and 6 mg or 6 and 12 mg)
Trial: 340643
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine (4 mg and 8 mg)
Trial: 340643
Drug: Intramuscular nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nalbuphine
Trial: 340643
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine and nalbuphine
Trial: 31163012
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy of adjuvant radiotherapy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m2 docetaxel once per week (Cohort A)
Trial: 31163012
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy of adjuvant radiotherapy with a simultaneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day (Cohort B)
Trial: 25757757
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy and hematoma volume
Trial: 20689451
Drug: NSAIDs (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (1200 mg)
Trial: 10815854
Drug: Troglitazone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone therapy
Trial: 1479419
Drug: Intramuscular recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular recombinant alpha 2b interferon (3 x 10(6)) administered every second evening for 6 months
Trial: 1479419
Drug: Aspecific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspecific treatment
Trial: 6335848
Drug: Conventional three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional three doses of DPT 3 months apart
Trial: 6335848
Drug: Both immunized
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both immunized groups (2-dose and 3-dose)
Trial: 9672328
Drug: Ketoprofen 75
RxNorm normalized name: ketoprofen 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 75 mg/day
Trial: 9672328
Drug: Acetaminophen 4000
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4000 mg/day
Trial: 28222674
Drug: 6% HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 130/0.4 administration
Trial: 28222674
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate Ringer's solution 7.5 mL/kg
Trial: 24194421
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (daily 25 mg)
Trial: 23031470
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g FB/kg DM diet
Trial: 23031470
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g FB/kg DM diet
Trial: 23031470
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g FB/kg DM diet)
Trial: 23031470
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g FB/kg DM diet
Trial: 23031470
Drug: Highest level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest level of FB (150 g FB/kg DM diet)